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Background: Chemoradiation (CRT) or short-course radiotherapy (SCRT) are
standard treatments for locally advanced rectal cancer (LARC). We evaluated the.e00804
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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alternative prior to total mesorectal excision (TME).
Methods/design: This multi-centre, phase II trial in patients with magnetic
resonance imaging (MRI) deﬁned high-risk LARC (>cT3b, cN2þ or extramural
venous invasion) randomised patients (1:1) to FOLFOX þ Bevacizumab (Arm 1)
or FOLFOXIRI þ bevacizumab (Arm 2) every 14 days for 6 cycles prior to
surgery. Patients were withdrawn if positron emission tomography (PET)
standardised uptake value (SUV) after 3 cycles failed to decrease by >30% or
increased compared to baseline. Primary endpoint was pathological complete
response rate (pCR). Secondary endpoints included adverse events (AE) and
toxicity. Neoadjuvant rectal (NAR) scores based on “T” and “N” downstaging
were calculated.
Findings: Twenty patients aged 18e75 years were randomised. The trial stopped
early because of poor accrual. Seventeen patients completed all 6 cycles of
NACT. One stopped due to myocardial infarction, 1 poor response on PET (both
received CRT) and 1 committed suicide. 11 patients had G3 AE, 1 G4 AE
(neutropenia), and 1 G5 (suicide). pCR (the primary endpoint) was 0/10 for Arm
1 and 2/10 for Arm 2 i.e. 2/20 (10%) overall. Median NAR score was 14$9 with
5 (28%), 7 (39%), and 6 (33%) having low, intermediate, or high scores. Surgical
morbidity was acceptable (1/18 wound infection, no anastomotic leak/pelvic
sepsis/ﬁstulae). The 24-month progression-free survival rate was 75% (95% CI:
60%e85%).
Interpretation: The primary endpoint (pCR rate) was not met. However,
FOLFOXIRI and bevacizumab achieved promising pCR rates, low NAR scores
and was well-tolerated. This regimen is suitable for testing as the novel arm
against current standards of SCRT and/or CRT in a future trial.
Keyword: Oncology
1. Background
Preoperative CRT followed by TME has become the international standard treatment
for patients with LARC. CRT improves local control, but has failed to enhance over-
all survival (OS). Tumor down-staging is achieved in only 50%, and a pCR in
10e25%. CRT delivers low doses of chemotherapy, and delays administration of
eﬀective systemic chemotherapy by 4e6 months Up to 30% of patients with
LARC still subsequently develop metastatic disease [1]. Pelvic radiotherapy is asso-
ciated with an increased risk of postoperative wound complications and long-term
adverse late-eﬀects (gastrointestinal, urological, psycho-sexual symptoms and
chronic pain) and an increased risk of second malignancy. Recent improvements
in the quality of surgery have also led to low local recurrence rates without radiation.on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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the breached muscularis propria in a sub-classiﬁcation of T3 tumors i.e. mrT3a ¼
<1 mm, mrT3b ¼ 1$01-5$00 mm, mrT3c ¼ 5$01-15$00 mm and mrT3d ¼
>15$01 mm, the distance to the mesorectal fascia and extramural venous invasion
(EMVI). Hence, risk adaptive strategies might be envisaged whereby chemotherapy
or radiotherapy is selected according to the relative risks of local or distant
recurrence.
In contrast to postoperative adjuvant chemotherapy, compliance with NACT is high
[2]. In the Grupo Cancer de Recto 3 study [3] 92% patients received full systemic
doses in the induction arm prior to CRT, compared with only 51% in postoperative
adjuvant arm (p ¼ 0.0001).
In colon cancer, the earlier the adjuvant chemotherapy following surgery, the more
eﬀective it is [4]. In rectal cancer, the optimal time to start chemotherapy may be
within 5e6 weeks [5], but surgical morbidity can delay delivery and increase the
risk of distant metastases [6].
Triplet schedules (FOLFOXIRI) with or without biological agents demonstrate high
response rates in metastatic disease, which led us to randomise between FOLFOX
and bevacizumab, and FOLFOXIRI and bevacizumab in the neoadjuvant setting.
The BACCHUS study examines the potential beneﬁt of doublet (FOLFOX) and
triplet (FOLFOXIRI) chemotherapy regimens in combination with bevacizumab,
and investigated whether intensive NACT alone without radiotherapy can be toler-
able with acceptable toxicity. We hoped to achieve a pCR rate in primary rectal can-
cer suﬃcient to warrant further investigation in a phase III study comparing current
standards of SCRT and/or 5FU based chemoradiotherapy with NACT alone.2. Methods
This multicentre, open-label, prospective, randomised phase II study
(NCT01650428) was approved by Riverside l Research Ethics Committee (ref:12/
LO/1158), and sponsored by University College London. All participants provided
written informed consent before inclusion in the trial.
In terms of the population of the study, patients with histologically conﬁrmed MRI-
deﬁned high-risk resectable adenocarcinoma of the rectum and World Health Orga-
nisation (WHO) performance status of 0e1 with no distant metastatic disease were
recruited. High-resolution thin-slice MRI (3 mm) was mandated for loco-regional
staging. Other eligibility criteria included distal tumour 4e12 cm from the anal
verge, with a predicted penetration of the muscularis propria by >1 mm extension
(i.e. minimum of cT3b) or T4a; cN2, and EMVI. Patients with tumour or suspectedon.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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ferential resection margin (CRM) were excluded.
The study objective was to demonstrate the eﬃcacy and safety of NACT alone in
LARC. The primary endpoint was pCR. Secondary endpoints included safety, toler-
ability and feasibility of delivering FOLFOX/FOLFOXIRI/Bevacizumab; overall
response rate (ORR), CRM negative (R0) resection rate, T and N stage down-
staging, Progression-free survival (PFS), Disease-free Survival (DFS), OS, local
control, 1 year colostomy rate, adverse events, compliance with chemotherapy treat-
ment, and tumour regression grade (TRG).
The completion rate of the neo-adjuvant treatment, pCR frequency, number of pa-
tients with a R0 resection were recorded. Adverse events were recorded and graded
according to the National Cancer Institute’s Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version v4.03.
We also used NAR score as a composite endpoint [7, 8] using a weighted combina-
tion of ﬁnal pathological nodal stage (ypN) and down-staging of T stage (mrT stage
to ypT stage) representing a pseudo-continuous variable with 24 possible discrete
scores, ranging from 0e100 [8].
Patient randomisation was performed centrally at the UCL trials centre and patients
were randomly assigned to one of two treatment arms using a minimisation algo-
rithm in a 1:1 ratio and stratiﬁed according to treating centre, gender and presence
or absence of EMVI.
The primary endpoint was pCR (ypT0N0). We considered a likely pCR rate of
15e20 % after standard ﬂuoropyrimidineebased CRT and 4% with radiotherapy
alone. The study was powered on the assumption that NACT would achieve a
pCR rate of 20%. Hence, with a type I error a ¼ 0$05 and a type II error b ¼
0$8, then 27 patients for the FOLFOX/Bevacizumab arm were required, and the
same number for the FOLFOXIRI/Bevacizumab arm. Assuming 10 % of patients
will be non-evaluable, 30 patients were to be recruited to each arm (i.e. a total of
60 patients). NACT would be considered promising and worth exploring further
in a randomised phase III trial if at least 4/27 pCRs (15%) were observed in each
arm. The trial was not powered to perform any direct comparisons between the
two arms.
Both arms delivered chemotherapy (FOLFOXIRI or FOLFOX) preoperatively with
bevacizumab every 2 weeks to a total of 6 cycles (bevacizumab omitted during cycle
6 i.e. the ﬁnal chemotherapy cycle before resection). See Fig. 1 for Treatment
schedule.
Arm 1 econsisted of Bevacizumab 5 mg/kg IV over 30e90 minutes (cycles 1e5),
Oxaliplatin 85 mg/m2 IV over 2 hours, Folinic acid 350 mg IV over 2 hours, 5FUon.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 1. Treatment schedule as planned.
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12 weeks.
Arm 2econsisted of Bevacizumab 5 mg/kg IV over 30e90 minutes (cycles 1e5),
Irinotecan 165 mg/m2 IV over 1 hour, Oxaliplatin 85 mg/m2 IV over 2 hours, Folinic
acid 350 mg IV over 2 hours and 5FU 3200 mg/m2 IV continuous infusion over 48
hours given every 2 weeks for 12 weeks.
Dose modiﬁcations for toxicity were permitted according to speciﬁed protocol
guidelines. Adverse events were monitored from informed consent to 3 months after
surgery.on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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measurements, which were subsequently centrally reviewed. Evaluation of SUV
changes in primary tumour with PET/CT was mandated prior to cycle 4. Response
was deﬁned as a decrease in SUV by 30% after 3 cycles compared to baseline. Pa-
tients who failed to respond came oﬀ trial, and were treated at investigators discre-
tion, but were expected to receive CRT prior to surgery. Patients also underwent
clinical response evaluation with MRI prior to cycle 4 and prior to surgery according
to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Surgery was speciﬁed as TME and performed between a minimum of 6 weeks after
the end of chemotherapy or 8 weeks after bevacizumab (>2 half-lives of bevacizu-
mab) to a maximum of 10 weeks after last administration of trial treatment. Surgical
morbidity was recorded with particular emphasis on anastomotic leakage and peri-
neal wound complications.
Pathological evaluation of resected specimens was performed according to the 3rd
edition of the Royal College of Pathologists’ guidelines using the 5th edition of
TNM [9]. In addition, to compare with mrT-substaging, ypT3 disease was sub-
divided into ypT3a, ypT3b, ypT3c and ypT3d disease according to the radial
outgrowth from the breached muscularis propria. pTRG is presented as data categor-
ised into ﬁve groups- pTRG 0, pTRG 1, pTRG 2, pTRG 3, and pTRG 4 using the
Dworak categories. Also, the quality of the resected specimen was evaluated with
separate scoring for the mesorectum and the anal canal (in abdominoperineal exci-
sions). pCR was deﬁned as complete regression in the primary tumour and associ-
ated lymph nodes (ypT0 ypN0) following embedding of the entire scar and
examination of at least three deeper levels per block, in keeping with RCPath
guidance.
Postoperative adjuvant chemotherapy was permitted according to local protocols.
Patients were followed every 6 months to 42 months after randomisation, to docu-
ment recurrence and survival. Postoperative investigations/surveillance were per-
formed according to local practice, but with a minimum of 2 CT scans in the ﬁrst
2 years. Progression-free survival (PFS) was deﬁned as time from randomisation
to disease progression or death, whichever occurs ﬁrst. Disease-free survival
(DFS) was deﬁned as the time from surgery with complete resection (R0) to relapse,
second colorectal primary or death from any cause, whichever occurred ﬁrst.3. Results
The study intended to recruit 27 patients in each arm. In the event seven sites in the
UK randomised 20 patients (10 in each arm) between May 2013 and August 2015.
Median age was 58 years. The trial stopped early because of poor accrual. Patienton.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Baseline characteristics.
Baseline
characteristics
Arm 1 Arm 2 Total
FOLFOX D Bevacizumab FOLFOXIRI D Bevacizumab
N [ 10 N [ 10 N [ 20
N (%) N (%) N (%)
Age in years
Median (range) 58 (36e70) 58 (34e70) 58 (34e70)
Sex
Female 4 (40%) 4 (40%) 8 (40%)
Male 6 (60%) 6 (60%) 12 (60%)
cT stage
mrT3b 5 (50%) 5 (50%) 10 (50%)
mrT3c 5 (50%) 3 (30%) 8 (40%)
mrT3d 0 (0%) 1 (10%) 1 (5%)
mrT4 (peritoneal
involvement)
0 (0%) 1 (10%) 1 (5%)
cN stage
mrN0 4 (40%) 0 (0%) 4 (20%)
mrN1 2 (20%) 5 (50%) 7 (35%)
mrN2 4 (40%) 5 (50%) 9 (45%)
mrEMVI
Absent 5 (50%) 6 (60%) 11 (55%)
Present 5 (50%) 4 (40%) 9 (45%)
ECOG performance status
Fully active (0) 8 (80%) 8 (80%) 16 (80%)
Ambulatory (1) 2 (20%) 2 (20%) 4 (20%)
Note: All patients were Class I for New York Heart Association Classiﬁcation at baseline.
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diagram.
A total of 8 (80%) patients in Arm 1 and 9 (90%) in Arm 2 completed all 6 intended
cycles of NACT. Three patients discontinued treatment early: one patient (Arm 2)
had not responded after 3 cycles, one (Arm 1) stopped treatment because of a
myocardial infarction during cycle 1 and one (Arm 1) committed suicide after 4 cy-
cles of treatment. There were no toxicity related deaths. The percentage dose deliv-
ered in relation to the planned dose for chemotherapy and bevacizumab was good
(see compliance in Table 2). Table 3 shows the percentage total dose delivered byon.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 2. Bacchus consort diagram.
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2e107) and 86$5 days (range: 30e117) in Arm 1 and Arm 2 respectively. Table
4 shows that treatment delays due to adverse events were more common amongst
patients in Arm 2 (60% versus 40%) but this did not impact on the delivered total
dose for any patient.
Table 5 lists all the treatment-related grade 1e4 adverse events during the study.
Twelve patients had at least 1 Grade 3 adverse event, and two patients G4 (one
G4 neutropenia). Table 6 shows the Acute Toxicity from NACT Bevacizumab.
A best response assessment (RECIST v1.1) at end of cycle 3 and/or end cycle 6 was
available for 19 patients. Of the patients who had at least one response assessment, a
total of 4 (21%) achieved a complete response (1 FOLFOX and 3 FOLFOXIRI), 12
(63%) achieved a partial response (8 FOLFOX and 4 FOLFOXIRI), and 3 (16%) had
stable disease as their best response (all FOLFOXIRI). There is no evidence of as-
sociation between the best overall response obtained and treatment group (Fishers’ p
¼ 0$09). The waterfall plot Fig. 3 shows the percentage change in the sum of the
longest tumour diameters observed along with the clinical response classiﬁcation
at end of NACT (cycle 6) compared to baseline. Of the 18 patients assessed by
PET/CT after cycle 3 in terms of the SUV, 7/8 (88%) in FOLFOX and 8/10on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 2. Treatment compliance.
Treatment summary Arm 1 Arm 2
FOLFOX D Bevacizumab FOLFOXIRI D Bevacizumab
N [ 10 N [ 10
Total number of chemo cycles given
1 1 (10%) 0 (0%)
3 0 (0%) 1 (10%)
4 1 (10%) 0 (0%)
6 8 (80%) 9 (90%)
Total number of Bevazizumab cycles given
1 1 (10%) 0 (0%)
3 0 (0%) 1 (10%)
4 1 (10%) 0 (0%)
6 8 (80%) 9 (90%)
Early treatment discontinuation
No 8 (80%) 9 (90%)
Yes 2 (20%) 1 (10%)
SAE (Myocardial infarction) 1 (10%) 0 (0%)
No response following 3 cycles 0 (0%) 1 (10%)
Suicide 1 (10%) 0 (0%)
Table 3. Percentage total dose delivered by chemotherapy drug.
Percentage total
dose delivered
Arm 1 Arm 2
FOLFOX D Bevacizumab FOLFOXIRI D Bevacizumab
N [ 10 N [ 10
Median (range) Median (range)
5FU 100% (16$7%e100%) 100% (50%e100%)
Bevacizumab 100% (20%e100%) 100% (60%e100%)
Folinic acid 100% (16$7%e100%) 100% (50%e100%)
Oxaliplatin 100% (16$7%e100%) 95$8% (50%e100%)
Irinotecan Not applicable 91$7% (50%e100%)
9 https://doi.org/10.1016/j.heliyon.2018.e00804
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Table 4. Reasons for chemotherapy delays.
Reasons for chemotherapy
delays
Arm 1 Arm 2
FOLFOX D Bevacizumab FOLFOXIRI D Bevacizumab
N [ 10 N [ 10
Administrative reason/error 3 (30%) 4 (40%)
Patient choice - 3 (30%)
Neutropenia 3 (30%) 6 (60%)
Febrile neutropenia - 1 (10%)
Respiratory tract infection - 1 (10%)
Thrombocytopenia 2 (20%) -
Other adverse event 1 (10%) -
Any adverse event related reason 4 (40%) 6 (60%)
Any reason 6 (60%) 8 (80%)
10 https://doi.org/10.1016/j.heliy
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cycle 3 compared with baseline.
Seventeen patients had tumour in the mid-rectum (>5e10 cm) and 3 in the upper
rectum (from >10 cm). Radical surgery was performed in 18/20 patients: anterior
resection (14), abdominoperineal excision of the rectum (3) and Hartmann’ proced-
ure (1). Surgery was not performed in one patient due to suicide and one patient
refused. Both had received FOLFOX and bevacizumab. Amongst patients who
had surgery in the FOLFOX arm, the median time from end of chemotherapy to sur-
gery was 59$5 days (range: 43e154 days). All patients in the FOLFOXIRI arm had
surgery with a median interval of 52$5 days (40e191 days). Of the 18 patients who
proceeded to surgeryesee Fig. 2 for consort diagrame 17/18 (94%) achieved an R0
resection. A total of 2/18 (11%) patients had a pCR (both in the FOLFOXIRI arm).
There were no life-threatening episodes from surgical morbidity (Table 7), and no
post-surgical deaths, although one patient developed an adhesional bowel obstruc-
tion 1 month after surgery. There was no evidence the addition of bevacizumab
adversely aﬀected surgical morbidity.
T and N down-staging were observed. The median NAR score in evaluable patients
was 14$9 with 5 (28%), 7 (39%), and 6 (33%) patients having low, intermediate, and
high scores. NAR scores after NACT are shown for each arm in Table 8. The
observed median NAR score for patients receiving FOLFOX was higher in compar-
ison to those receiving FOLFOXIRI but not statistically signiﬁcant (FOLFOX:
17$69, range: 8$43e65$04; FOLFOXIRI: 6$09, range: 0e50$36, p ¼ 0$07). A
comparison of clinical stage, pathological stage and NAR scores is shown in
Table 9, Fig. 4.on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 5.Worst grade experienced during the study (grade 1 & 2 and grade 3 & 4)
by arm and by treatment.
Worst grade
experienced during
the study CTCAE
term v4.03
Grade 1 & 2 Grade 3 & 4
Arm 1 Arm 2 Arm A Arm B
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
N [ 10 N [ 10 N [ 10 N [ 10
Blood and lymphatic
system disorders
5 (50%) 8 (80%) - 2 (20%)
Anemia 5 (50%) 9 (90%) - -
Bone marrow hypocellular - - - 1 (10%)
Febrile neutropenia 1 (10%) 1 (10%) - 1 (10%)
Leukocytosis - 2 (20%) - -
Cardiac disorders - - 1 (10%) -
Acute coronary syndrome - - 1 (10%) -
Atrial ﬁbrillation 1 (10%) - - -
Eye disorders 1 (10%) - - -
Blurred vision 1 (10%) - - -
Gastrointestinal
disorders
5 (50%) 8 (80%) 5 (50%) 2 (20%)
Abdominal distension - 1 (10%) - -
Abdominal pain 4 (40%) 8 (80%) 2 (20%) 2 (20%)
Anal pain 1 (10%) - - -
Colonic obstruction - - 1 (10%) -
Constipation 2 (20%) 8 (80%) 1 (10%) -
Diarrhea 5 (50%) 8 (80%) 2 (20%) -
Gastroesophageal reﬂux
disease
1 (10%) 1 (10%) - -
Mucositis oral 4 (40%) 3 (30%) - -
Nausea 5 (50%) 8 (80%) - -
Rectal haemorrhage 1 (10%) - - -
Rectal pain 1 (10%) - - -
Small intestinal obstruction - - 1 (10%) -
Vomiting 5 (50%) 5 (50%) 1 (10%) -
General disorders and
administration site
conditions
8 (80%) 8 (80%) - 2 (20%)
Fatigue 8 (80%) 8 (80%) - 2 (20%)
Fever - 1 (10%) - -
Pain 1 (10%) 1 (10%) - -
Immune system disorders 1 (10%) 1 (10%) - -
(continued on next page)
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Table 5. (Continued )
Worst grade
experienced during
the study CTCAE
term v4.03
Grade 1 & 2 Grade 3 & 4
Arm 1 Arm 2 Arm A Arm B
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
N [ 10 N [ 10 N [ 10 N [ 10
Allergic reaction 1 (10%) 1 (10%) - -
Infections and
infestations
3 (30%) 4 (40%) - 1 (10%)
Bronchial infection 1 (10%) - - -
Catheter related infection 1 (10%) 1 (10%) - -
Pelvic infection 1 (10%) - - -
Sepsis 1 (10%) - - -
Upper respiratory infection - 3 (30%) - -
Urinary tract infection - 2 (20%) - -
Wound infection - 1 (10%) - 1 (10%)
Injury, poisoning and
procedural
complications
2 (20%) 1 (10%) - 1 (10%)
Wound complication 2 (20%) 1 (10%) - 1 (10%)
Wound dehiscence - - - 1 (10%)
Investigations 7 (70%) 7 (70%) 1 (10%) 3 (30%)
Activated partial
thromboplastin time
prolonged
2 (20%) 3 (30%) - -
Alanine aminotransferase
increased
4 (40%) 4 (40%) - -
Alkaline phosphatase
increased
1 (10%) 3 (30%) - -
Aspartate aminotransferase
increased
3 (30%) 3 (30%) - -
Blood bilirubin increased 1 (10%) 1 (10%) - -
Creatinine increased 1 (10%) 2 (20%) - -
GGT increased 2 (20%) 4 (40%) - 1 (10%)
Lymphocyte count
decreased
1 (10%) 3 (30%) - -
Lymphocyte count
increased
- 1 (10%) - -
Neutrophil count decreased 4 (40%) 6 (60%) 1 (10%) 2 (20%)
Other investigations - 1 (10%) - -
Platelet count decreased 3 (30%) 4 (40%) - -
Weight loss 1 (10%) - - -
(continued on next page)
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Table 5. (Continued )
Worst grade
experienced during
the study CTCAE
term v4.03
Grade 1 & 2 Grade 3 & 4
Arm 1 Arm 2 Arm A Arm B
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
N [ 10 N [ 10 N [ 10 N [ 10
White blood cell decreased 3 (30%) 5 (50%) - -
Metabolism and nutrition
disorders
4 (40%) 7 (70%) - 1 (10%)
Anorexia 2 (20%) 5 (50%) - -
Hypoalbuminemia 1 (10%) 3 (30%) - -
Hypokalemia 1 (10%) 2 (20%) - -
Hyponatremia 2 (20%) 2 (20%) - 1 (10%)
Musculoskeletal and
connective tissue
disorders
1 (10%) 2 (20%) - -
Arthralgia - 1 (10%) - -
Back pain - 1 (10%) - -
Other musculoskeletal and
connective tissue
disorders
1 (10%) - - -
Nervous system disorders 7 (70%) 8 (80%) - -
Dysesthesia 2 (20%) 4 (40%) - -
Headache - 2 (20%) - -
Paresthesia 1 (10%) - - -
Peripheral sensory
neuropathy
6 (60%) 8 (80%) - -
Psychiatric disorders 1 (10%) 1 (10%) - -
Anxiety 1 (10%) - - -
Insomnia - 1 (10%) - -
Renal and urinary
disorders
3 (30%) 2 (20%) 1 (10%) -
Acute kidney injury - - 1 (10%) -
Proteinuria 2 (20%) 1 (10%) - -
Urinary retention 1 (10%) 1 (10%) - -
Reproductive system and
breast disorders
2 (20%) 2 (20%) - -
Ejaculation disorder 1 (10%) - - -
Pelvic pain 1 (10%) 2 (20%) - -
Respiratory, thoracic and
mediastinal disorders
1 (10%) 2 (20%) - -
Cough - 1 (10%) - -
(continued on next page)
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Table 5. (Continued )
Worst grade
experienced during
the study CTCAE
term v4.03
Grade 1 & 2 Grade 3 & 4
Arm 1 Arm 2 Arm A Arm B
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
N [ 10 N [ 10 N [ 10 N [ 10
Dyspnea - 1 (10%) - -
Epistaxis 1 (10%) - - -
Laryngospasm 1 (10%) - - -
Other respiratory, thoracic
and mediastinal
disorders
1 (10%) 1 (10%) - -
Pharyngeal mucositis - 1 (10%) - -
Sore throat - 1 (10%) - -
Skin and subcutaneous
tissue disorders
- 4 (40%) - -
Alopecia - 4 (40%) - -
Palmar-plantar
erythrodysesthesia
syndrome
- 1 (10%) - -
Vascular disorders 1 (10%) 2 (20%) 1 (10%) 5 (50%)
Hot ﬂashes - 1 (10%) - -
Hypertension 1 (10%) 2 (20%) 1 (10%) 4 (40%)
Hypotension - 1 (10%) - 1 (10%)
Any adverse event 4 (40%) 2 (20%) 6 (60%) 8 (80%)
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three deaths were reported, of which one was suicide and two due to disease progres-
sion, one of which related to a second malignancy (malignant melanoma). Two other
patients in Arm 1 progressed, one patient refused surgery and received brachyther-
apy but subsequently relapsed at the primary site, and the other in liver. In Arm 1, the
2-year OS rate was 80% (95% CI: 41%e95%) and the 2-year PFS rate 60% (95% CI:
25%e83%).
No deaths or progressions were reported in Arm 2. OS and PFS survival curves by
arm are shown in Figs. 5 and 6.
The results of imaging with PET, mriTRG and MRI diﬀusion weighted imaging and
RECIST, TRG and tumour cell density along with the translational results will be
presented in a separate report.on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 6. Toxicity from BevacizumaB (BVZ) within NACT e acute toxicity.
CTCAE 4.03 AE
term worst grade
Grade 1e2 Grade 3e5
FOLFOX/
BVZ
FOLFOXIRI/
BVZ
FOLFOX/
BVZ
FOLFOXIRI/
BVZ
Bleeding/haemorrhage
Rectal haemorrhage 1 - - -
Fistula - - - -
None - - - -
Gastrointestinal perforation - - - -
None - - - -
Heart failure - - - -
Acute coronary syndrome - - 1 -
Hypertension (grades 3 e 5 only) - - - -
Hypertension - - 1 4
Proteinuria - - - -
Proteinuria 2 1 - -
Reversible Posterior
Leukoencephalopathy Syndrome
(RPLS)
- - - -
None - - - -
Thromboembolic events (arterial
and venous)
- - - -
None - - - -
Wound complication - - - -
Wound complication 2 1 - 1
Wound dehiscence - - - 1
Pelvic sepsis 1 - - -
Note: numbers represent frequency of patients.
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To our knowledge, the BACCHUS trial is the only NACT clinical trial which has
investigated the combination of a triplet-chemotherapy backbone with bevacizumab
in patients with rectal cancer. Because accrual ended early, neither of the 2 study
arms met the primary endpoint of achieving a pCR of 4/27 (15%). On this basis,
neither of the investigational strategies appear to merit further investigation. Never-
theless, the trial provides important data, not least because Arm 2 (FOLFOXIRI and
bevacizumab) showed a pCR of 2/10 (20%) in a high-risk group where 5/10 (50%)
had baseline mrEMVI (an independent prognostic factor for poor outcomes in rectal
cancer).
The FOLFOXIRI plus bevacizumab arm is also promising in terms of RECIST
response, pathological down-staging, pCR and the low NAR scores. Otheron.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. Waterfall plot of changes in the tumour size at end of cycle 6 assessment by treatment. Only 16
patients had an assessment for response at end of cycle 6. The patients marked in bold colours (3 pa-
tients) did not have an assessment for response at end of cycle 6. For these patients, the response showed
in this graph was the one assessed at end of cycle 3. There are 19 patients with a response assessment at
either end of cycle 3 or cycle 6.
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combined with bevacizumab compared with NACT alone [10]. A recent meta-
analysis of targeted agents added to neoadjuvant therapy in rectal cancer suggested
that bevacizumab enhances the pCR rate with a pooled estimate of 27% (95% CI,
21e34%) [11].
We have shown that NACT with FOLFOX and bevacizumab or FOLFOXIRI and
bevacizumab without preoperative SCRT or CRT in patients with localised but
high-risk rectal cancer is safe, with acceptable toxicity. There have been concerns
regarding excessive surgical morbidity with intensive NACT e if bevacizumab is
administered, and particularly when combined with preoperative radiation, but in
BACCHUS there was no increase in anastomotic leaks, pelvic sepsis or ﬁstulae,
even with the addition of bevacizumab. Neither diarrhoea nor neutropenia were
enhanced with the addition of irinotecan in Arm 2 (FOLFOXIRI þ Bevacizumab),
although 4/10 experienced some hair loss.
The primary endpoint was pCR in the TME specimen. We had hoped the
BACCHUS regimens would produce a pCR rate comparable to CRT, but only 2/
18 (11%) achieved pCR (both received FOLFOXIRI þ bevacizumab). FOLFOXIRI
and bevacizumab appears active as 4/10 (40%) achieved a complete clinical
response. Other studies of NACT alone with and without bevacizumab in rectalon.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 7. Complications within 3 months post-surgery by arm and severity.
Reported post-surgical
complications (48 hours,
1 month or 3 months
post-surgery
Grade 1 & 2 Grade 3 & 4
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
FOLFOX D
Bevacizumab
FOLFOXIRI D
Bevacizumab
N N N N
Post-surgical complication
Abdominal pain 1 - - -
Bowel obstruction - - 1 -
Breakdown of perineal
wounda
- - - 1
Diarrhoea - - 1 -
Hypotension - 2 - -
Loss of leg mobility 1 - - -
Parastomal hernia 1 - - -
Pelvic sepsis 1 - - -
Perineal hernia - - - 1
Pulmonary complications - 1 - -
Urinary tract infection - 2 - -
Urinary retention - 1 - -
Vomiting 1 - - -
Wound infection/
complication
1 - - 1
aAt 3 months post-surgery.
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(Table 10) [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24], but some have
included more liberal entry criteria, less advanced tumours and less in-depth pathol-
ogy assessment without a deﬁned dissection protocol for pCR.Table 8. NAR status after NACT for each arm.
NAR status Arm 1 Arm 2
FOLFOX D Bevacizumab FOLFOXIRI D Bevacizumab
N [ 10 N [ 10
NAR status
Low (NAR<8) 0 (0%) 5 (50%)
Intermediate (NAR 8 e NAR 16) 4 (40%) 3 (30%)
High (NAR>16) 4 (40%) 2 (20%)
Not evaluablea 2 (20%) 0 (0%)
Note: Patients 1 (Arm B FOLFOXIRI þ Bevacizumab) and 17 (Arm A FOLFOX þ Bevacizumab) did
not receive all planned cycles of chemotherapy.
a NAR score for patient 7 and 9 could not be calculated as they did not undergo surgery.
on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 9. Clinical versus pathological staging and interval for NAR scoring.
Id Arm Baseline Best OR Wks from end of NACT to surgery Resect ypT ypN Regression NAR Relapsed or
died
cT stage cN stage MRI EMVI
2 1 T3c N2 Y PR 6$3 R0 ypT2 pN1 Good 20$4 NO
3 1 T3b N2 N PR 6$4 R0 ypT2 pN0 Minimal 8$4 NO
6 1 T3b N2 N PR 11$9 R0 ypT3a pN0 None 15$0 Yes
7 1 T3b N0 N PR Refused surgery Yes
9 1 T3c N0 Y PR No surgery suicide Yes
11 1 T3c N0 N PR 10$9 R0 ypT3a pN0 Good 15$0 NO
14 1 T3b N1 N CR 7$6 R0 ypT2 pN0 Moderate 8$4 NO
16 1 T3c N2 Y PR 6$6 R2 ypT4 pN2 Minimal 65$0 Yes
17 1 T3c N0 Y PR 22$1 R0 ypT2 pN1 Moderate 20$4 NO
18 1 T3b N1 Y PR 9$7 R0 ypT3a pN2 Minimal 50$4 Yes
1 2 T3c N2 Y SD 27$4 R0 ypT2 pN1 Moderate 30$1 NO
4 2 T3b N1 N PR 6$1 R0 ypT2 pN0 Moderate 8$4 NO
5 2 T3c N2 Y PR 7$9 R0 ypT3b pN0 Moderate 15$0 NO
8 2 T3b N2 N CR 9$4 R0 ypT0 pN0 Total 0$9 NO
10 2 T3b N2 Y SD 7$1 R0 ypT3c pN0 Minimal 15$0 NO
12 2 T4 N1 N CR 5$9 R0 ypT0 pN0 Total 0 NO
13 2 T3b N1 N PR 7$4 R0 ypT1 pN0 Moderate 3$7 NO
(continued on next page)
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Table 9. (Continued )
Id Arm Baseline Best OR Wks from end of NACT to surgery Resect ypT ypN Regression NAR Relapsed or
died
cT stage cN stage MRI EMVI
15 2 T3b N1 Y CR 8$7 R0 ypT1 pN0 Good 3$7 NO
19 2 T3c N1 N SD 7$4 R0 ypT3b pN2 Moderate 50$4 NO
20 2 T3d N2 Y PR 9$7 R0 ypT1 pN0 Good 3$7 NO
Three patients discontinued treatment early. Patient 1 in FOLFOXIRI arm did not respond according to SUV after 3 cycles; patient 17 in the FOLFOX arm stopped treatment in cycle 1 due to
myocardial infarction and patient 9 committed suicide after 4 cycles of treatment.
Arm 1 ¼ FOLFOX plus Bevacizumab, Arm 2 ¼ FOLFOXIRI plus Bevacizumab; cT stage ¼ clinical Tumour stage (TNM); cN ¼ clinical nodal stage (TNM); MR EMVI ¼ extramural vascular
invasion deﬁned on staging MRI; OR ¼ overall response; PR ¼ clinical partial response; CR¼ clinical complete response; R0 ¼ curative resection with margin >1 mm; ypT¼ pathological tumour
T stage after treatment; ypN ¼ pathological nodal stage after treatment; NAR ¼ neoadjuvant rectal score.
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Fig. 4. NAR scores by treatment group. A nonparametric K-sample test on the equality of medians p-
value is 0$066. This suggests no evidence of a diﬀerence in the medians of NAR scores between treat-
ment groups at a 5% signiﬁcance level.
Fig. 5. Overall survival according to treatment arm.
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down-staging and as a surrogate endpoint for clinical trials involving CRT [7].
Data from 1,479 patients within the NSABP R04 trial, showed that low, intermediate
and high risk of death categories, based on tertiles of the NAR score, were signiﬁ-
cantly associated with 5-year OS (p < 0.0001) e giving values of 92%, 89%, and
68 %, respectively [7]. Others have also shown lower NAR scores correlate with
improved 5-year OS (p < 0$0001) [25], and outperform pCR [26]. Further studies
have shown 5-year overall survival of 84%, 71%, and 59% for low-, intermediate-,on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 6. Progression-free survival according to treatment arm.
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has recently been validated with individual-level surrogacy according to Prentice
criteria for DFS within the CAO/ARO/AIO-04 randomized phase 3 trial, and is
approved by the National Cancer Institute as a surrogate primary endpoint in phase
II rectal cancer clinical trials assessing neoadjuvant CRT. However, the NAR score
has not previously been used to assess outcomes from NACT alone and will require
validation.
In BACCHUS, median NAR score in evaluable pts was 14$9 with 5 (28%), 7 (41%),
and 5 (30%) patients having low, intermediate, and high NAR scores. These compare
favourably with a recent retrospective analysis in patients treated with preoperative
CRT, which showed 193/522 (37$0%) had low, 183/522 (35$0%) intermediate, and
146/522 (28$0%) showed high NAR scores [28]. FOLFOXIRI and bevacizumab
was particularly active in terms of the NAR score (See Table 6 and Fig. 3).
The strengths of BACCHUS reﬂect the MRI-deﬁned high risk entry criteria, an
intensive triplet chemotherapy regimen, the high quality of surgery and a clear deﬁ-
nition of the primary endpoint. In this selected high-risk population (making up
about 40% of rectal cancers overall) the risk of distant relapse predominates over
local recurrence. FOLFOXIRI and bevacizumab is a highly active regimen. A recent
meta-analysis of FOLFOXIRI-Bevacizumab studies involving 877 patients in colo-
rectal cancer with initially unresectable metastatic disease reported an objective
response rate of 69% (95% CI, 65%e72%; I2 ¼ 25%) [29]. The Neoadjuvant FOL-
FOX 6 Chemotherapy With or Without Radiation in Rectal Cancer (FOWARC) trialon.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 10. Studies of neoadjuvant chemotherapy without radiation.
No of ptsa Eligibility NACT Acute Toxicity PCRb Ro resection Outcomes
Ishii 2010 [12] 26 T3/T4 N0-2 Irinotecan (80 mg/
m2), FUFA days 1, 8,
and 15 for 4 weeks
Not stated 1/15 (7%) Not stated 5 year RFS 74%
OS 84%
Fernandez-Martos
2014 [13]
46 T3 middle third
tumors 2 mm from
the mesorectal fascia
Capox þ bev 2 acute toxic deaths
13% rate of
anastomotic leak
higher than expected
(1 death)
9/46 (19$5%) 96$4% No data
Uehara 2011, 2013
[14,15]
32 T3 >5 mm, T4, N2,
CRM involved/at risk
Capox þ bev Postop complication
in 43%
8/32 (12.5%) 84$3% No data
Schrag 2014 [16] 32 T2N1, T3 any N (not
N2 bulky) Not T4
5e12 cm from anal
verge
FOLFOX þ bev (6
cycles bev 1e4)
2 pts withdrew
(angina arrhythmia)
8/32 (25%) 100% RFS 92%
OS 91%
AlGizawy 2015 [17] 45 C Stage II and III 6 cycles of FOLFOX
6
3 pelvic collections 2
delayed wound
healing
8/45 (17$8% No data 3 year DFS 68%
3 year OS 81%
Hasegawa 2017 [18]
(UMIN000005654)
60 C Stage II and III mFOLFOX6) þ bev
or cetuximab,
depending on KRAS
status
Postop complication
rate (grade 2)
21$7%
10/60 (16$7%) 98$3% No data
Matsumoto 2015 [19]
retro-spective
15 cT3/cT4a, cNþ FOLFOX (60%) IRIS
FOLFIRI
3/15 (20%) grade 3/4
adverse events
2/15 (13$3%) 100% 5-year RFS rate
66$7% and 62$6% in
NAC non-NAC
(continued on next page)
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Table 10. (Continued )
No of ptsa Eligibility NACT Acute Toxicity PCRb Ro resection Outcomes
groups
Ueki 2016 [20] 31 Clinical stage II/III
lower rectal cancer
XELOX Grade 3e4 adverse
events in 9/31 (31%).
3/29 (10$3%) 96$5% No data
Kamiya 2016 [21]
CORONA 1 trial
phase II
41 cT3/T4 cNþ XELOX Major complication in
6/40 patients (15$0%).
5/41 (12$2%) 37/41
90$3%
No data
FOWARC trial Deng
2016 [22]
163 MRI or CT þ EUS
stage II (T3-4/N0) or
stage III (T1-4/N1-2),
M0, <12 cm above
anal verge
modiﬁed FOLFOX6
alone
Low 10/152 (6$6%) 136/152 (89%) No data
FACT trial Koike
2017 [23]
52 T3 or T4 stage II/III
rectal cancer
FOLFOX Safe 5/42 resected
(11$9%) 5/52
overall
91% No data
GRECCAR 4 Rouanet
2017 [24]
10 Mri deﬁned cT3  c,
cT4 or predicted CRM
 1 mm
FOLFIRINOX Grade 3e4 toxicity in
7/11 (63$6%)
1/10 (10%) 10/10 (100%) No data
BACCHUS present
study
20 Mri deﬁned high risk
> T3b
Modiﬁed FOLFOX6
alone FOLFOXIRI
plus Bevacizumab
1 pelvic sepsis
2 wound infections no
leaks
2/20
10%
17/18 (94%)
resected
2 year
OS 80%
aNumber entering study.
b Number having had surgery.
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late eﬀects may be expected to be less severe with NACT than after CRT.
However, there are limitations. The trial stopped early because of poor accrual after
only 20 patients. Some centres were unwilling to forego CRT. The design of the
BACCHUS trial could be criticised for the restrictive patient selection, which limits
its applicability to the “real world”. An upper age limit of 75 years was mandated
with PS 0e1, and current smokers were ineligible. The average of only 1e3 patients
per year in individual centres could indicate a signiﬁcant selection bias towards
younger ﬁtter patients.
In BACCHUS, a long interval (6e8 weeks) was mandated between NACT and sur-
gery for safety reasons. The median interval from the end of cytotoxic treatment until
surgery was 56 days, but from the ﬁnal dose of bevacizumab was 72 days (range
20e107 days) in Arm 1 and 86 days (range 30e117 days) in Arm 2 respectively.
This delay could have been responsible for less surgical morbidity, there were no
anastomotic leaks or pelvic sepsis. However, this interval could also be criticized
as being too long, allowing regrowth of the tumour in some patients.
The results of BACCHUS compare favourably with previous NACT studies. The
Grupo Espa~nol Multidisciplinar en Cancer Digestivo (Gemcad 0801) study achieved
a 15% pCR with XELOX þ bevacizumab [13] in an MRI deﬁned population in 46
patients without any radiotherapy. mrEMVI, at baseline was deﬁned in 23/46 (50%)
patients compared with 9/20 (45%) in BACCHUS.
However, the GEMCAD 0801 trial reported a higher than expected anastomotic leak
rate of 13%, with a 3- to 4-week interval (21e28 days) between completion of
chemotherapy and surgery [13]. In a Japanese study, a total 10/30 (43%) patients
with LARC treated with XELOX and bevacizumab NACT also developed surgical
morbidities [15].
A feasibility study in a less restricted group of patients (WHO 0e2, no age limit)
with clinical stage II-III rectal cancer (but not T4 tumours) used NACT alone
with FOLFOX þ Bevacizumab without radiotherapy [16]. R0 resection rate was
the primary outcome and pCR was reported in 8/29 resected patients (27%). Surgical
morbidity is not described but there was a single postoperative death attributed to
dehydration from high-volume ileostomy output. The 4-year DFS rate was 84%
and local recurrence was 0% [16].
Based on these results, a large multi-centre ongoing Phase III study (CALGB PROS-
PECT/Allianz N1048 trial) compares standard CRT against chemotherapy using
FOLFOX, and examines the selective use of CRT, depending on response to FOL-
FOX alone (NCT01515787). The primary endpoints are time to local recurrence and
DFS.on.2018.e00804
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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As the quality of TME improves, fewer patients with rectal cancer beneﬁt from
radiotherapy (which is a local treatment). Hence, the ‘blanket use’ of radiotherapy
is outdated. We need to validate preoperative biomarkers, which predict a high
risk of systemic recurrence such as EMVI, and can be imaged on MRI. The potential
advantages of NACT in place of RT include the ability to reduce the risk of micro-
metastases, and to spare patients from the morbidity of pelvic radiotherapy. In future
trials, we need to test these biomarkers to estimate prospectively the relative merits
of CRT and NACT for the individual.
Previous phase II trials in NACT have had heterogeneous inclusion criteria, few pa-
tients and uncertain surgical and MRI quality. The BACCHUS trial shows the deliv-
ery of FOLFOXIRI þ Bevacizumab is feasible, safe, and eﬀective in MRI deﬁned
high-risk LARC. This triplet combination allows early exposure to an eﬀective sys-
temic regimen, without impacting on compliance or surgical morbidity. Early onco-
logical outcomes in this small number of patients seem promising even in the context
of adverse features with EMVI. These ﬁndings support ongoing eﬀorts to shift sys-
temic treatments in LARC into the neoadjuvant setting and suggest that delivering
neoadjuvant chemotherapy could be as eﬀective as chemoradiation. If high propor-
tions of complete responses and similar NAR scores can be replicated, high-risk pa-
tients with locally advanced rectal cancer could have improved survival and
simultaneously avoid the harmful eﬀects of pelvic radiation. For this reason, FOL-
FOXIRI þ bevacizumab should be explored in a large phase III trial in patients at
high risk of systemic relapse and low risk of local relapse against the current standard
of routine SCPRT or CRT, and if validated can be translated into an alternative in
everyday practice.Declarations
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